N/A N=108 Pruritus in Patients With Chronic Kidney Disease
Kidney Failure, Chronic · Pruritus
Primary: Visual Analog Scale (VAS) — 3.35 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=80 Uric Acid and the Endothelium in CKD
Kidney Disease
Primary: Change in Endothelial Dependent Dilation From Baseline to Week 12 — 0.2; 0.9 % change — p=0.47
Phase 3 N=149 Alkali Therapy in Chronic Kidney Disease
Chronic Kidney Disease · Metabolic Acidosis
Primary: Sit to Stand to Sit Speed: Time Taken to Sit to Stand to Sit 10 Times — 23.8; 22.9 seconds
Phase 2 N=26 Lowering Serum Uric Acid to Prevent Acute Kidney Injury
Hyperuricemia
Primary: Number of Patients With Acute Kidney Injury (AKI). — 13; 13 Participants
N/A N=21 The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease
Uremic Pruritus
Primary: Visual Analogue Scale (VAS) Score for Pruritus — -3.38; -3.53 Units on a scale — p=<0.05
N/A N=4 Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
N/A N=22 Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients
End Stage Renal Disease
Primary: High Sensitivity C-reactive Protein (hsCRP) — 4.67; 15.11 mg/dl — p=0.008
N/A N=14 Chronic Kidney Disease Among Frail Elderly
Chronic Kidney Disease
Primary: Mortality — 0; 0 percentage of mortality
Phase 4 N=38 Rifaximin Therapy in Chronic Kidney Disease
Chronic Kidney Disease
Primary: Change in Serum Trimethylamine N-oxide (TMAO) — -3.9; 0.5 uM
Phase 2 N=60 Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria
Hyperuricemia · Albuminuria · Type 2 Diabetes
Primary: Urinary Albumin to Creatinine Ratio (UACR) — -48.65; -15.31 Precent change
Phase 2 N=20 Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis
Chronic Renal Failure
Primary: Change in Daily Urine Volume From Baseline — 18.3 mL
Phase 3 N=74 The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
Chronic Renal Insufficiency · Proteinuria
Primary: Effect of Vitamin D Supplementation on Albuminuria in CKD Patients as Assessed by Urine Albumin/Creatinine Measures. — 1126.68; 1061.39 mg/gram creatinine
Phase 2 N=15 The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome
End Stage Renal Disease
Primary: Change in Plasma Concentration Measure of Indoxyl Sulphate (IS) — -25.31; 9.71 µM/ml
Phase 3 N=258 To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Chronic Kidney Disease Associated Moderate to Severe Pruritus
Primary: Percentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 12 — 38.5; 47.7; 32.4…
Phase 2 N=24 Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
ESRD
Primary: Change in Leucine Disposal Rate (LDR) — -0.011; 0.005; 0.001 mg/kg/min — p=0.37
N/A N=31 Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function
Hemodialysis · Kidney Failure, Chronic
Primary: QOL: Kidney Disease Quality of Life (KDQOL36) — 74; 72 score on a scale
N/A N=20 Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease
Metabolic Acidosis · Chronic Kidney Disease
Primary: Change in Brachial Artery Flow Mediated Dilation (FMD) — 1.1; -0.7 absolute change in percent FMD
Phase 4 N=28 Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients
Pruritis
Primary: Investigator Global Assessment — 2.63; 2.32 units on a scale
Phase 4 N=47 Beneficial Effect of Probiotics on Chronic Kidney Disease
Chronic Kidney Disease
Primary: the Occurrence of Cardiovascular Event and Peritonitis Events — 0; 0; 0; 0 participants — p=>0.05
Phase 2 N=32 Exercise Intolerance in Renal Failure
Kidney Failure, Chronic
Primary: Change in Resting Muscle Sympathetic Nerve Activity (MSNA) — -7.5; 3.2 bursts/minute
N/A N=34 Ultrafiltration Profiling and Outcomes Among Individuals on Maintenance Hemodialysis
End Stage Renal Disease
Primary: Occurrence of Intradialytic Hypotension (Intradialytic Hypotension Defined as Nadir Systolic BP <90 mmHg) — 578; 571 Number of occurrences — p=0.5
N/A N=781 Chronic Kidney Disease (CKD) Guideline Adherence - A Quality Improvement Study
Chronic Renal Insufficiency
Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04
Phase 3 N=100 Omega 3 Fatty Acids in Patients With Chronic Renal Disease
Renal Insufficiency, Chronic
Primary: Number of Participants With a Urine Albumin Excretion Decrease of 20% or More — 19; 13 Participants — p=0.257
Phase 3 N=289 Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
Anemia, Iron Deficiency · Hyperphosphatemia · Renal Insufficiency, Chronic
Primary: Number of Participants Achieving a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality — 35; 46 Participants — p=.1602
Phase 3 N=188 Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)
Heart Failure
Primary: Change in Serum Creatinine — -0.04; 0.23 mg/dL
N/A N=10 Role of Extrarenal 1-Alpha-Hydroxylase in Patients With End Stage Renal Disease
End-Stage Renal Disease
Primary: Change in Monocyte VDR Expression With Vitamin D Therapy — 1899 units on a scale
N/A N=125 Home-base Kidney Care in Zuni Indians
Chronic Kidney Disease
Primary: Patient Activation Measure (PAM) -13 Item Questionnaire — 9.1; -1.4 points — p=0.01
Phase 2 N=55 A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
Hyperphosphatemia · End-stage Renal Disease
Primary: The Difference in Serum Phosphorus Between Baseline (Day 0) and End of Treatment (Day 28) — 5.9; 5.4 mg/dL
Phase 3 N=836 Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
Anemia · End Stage Renal Disease (ESRD)
Primary: Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)] — 0.428; 0.193 g/dL — p=<0.001
Phase 4 N=17 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
End-stage Renal Disease · Cardiovascular Disease
Primary: Pharmacokinetic Parameters of Ranolazine — 0.65 mcg/mL